A sub-analysis of the SAGE study in Italy indicates good glycemic control in type 1 diabetes.
Glycemic control
SAGE (Study of adults' GlycEmia)
Type 1 diabetes
Journal
Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
27
04
2022
revised:
01
11
2022
accepted:
03
11
2022
pubmed:
21
1
2023
medline:
25
2
2023
entrez:
20
1
2023
Statut:
ppublish
Résumé
Intensive glycemic control minimizes the risk of micro- and macrovascular complications in patients with type 1 diabetes (T1D). We report glycemic control in Italian participants (age groups: 26-44, 45-64, and ≥65 years) of the global SAGE study. The primary endpoint was proportion of participants who achieved an HbA Glycemic control can be considered good in the Italian SAGE cohort, especially in younger patients, who more frequently use pumps/continuous glucose monitoring. Greater patient education and use of technology may further support this achievement. Patients should be encouraged to maintain a low BMI and adhere to their diet.
Sections du résumé
BACKGROUND AND AIMS
Intensive glycemic control minimizes the risk of micro- and macrovascular complications in patients with type 1 diabetes (T1D). We report glycemic control in Italian participants (age groups: 26-44, 45-64, and ≥65 years) of the global SAGE study.
METHODS AND RESULTS
The primary endpoint was proportion of participants who achieved an HbA
CONCLUSIONS
Glycemic control can be considered good in the Italian SAGE cohort, especially in younger patients, who more frequently use pumps/continuous glucose monitoring. Greater patient education and use of technology may further support this achievement. Patients should be encouraged to maintain a low BMI and adhere to their diet.
Identifiants
pubmed: 36670006
pii: S0939-4753(22)00450-1
doi: 10.1016/j.numecd.2022.11.008
pii:
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
631-639Investigateurs
Roberto Anichini
(R)
Alice Magiar
(A)
Cristiana Maria Baggiore
(C)
Olga Disoteo
(O)
Antonella Porcu
(A)
Enzo Bonora
(E)
Maddalena Trombetta
(M)
Daniela Bruttomesso
(D)
Federico Boscari
(F)
Mario Carrano
(M)
Maria Gisella Cavallo
(M)
Marco Giorgio Baroni
(M)
Alberto Di Carlo
(A)
Ilaria Casadidio
(I)
Maurizio Di Mauro
(M)
Angelo Foglia
(A)
Anna De Simone
(A)
Lucia Frittitta
(L)
Gabriella Garrapa
(G)
Bruno Giorda
(B)
Elisa Nada Chieri
(E)
Giuseppina Guarino
(G)
Sandro Gentile
(S)
Concetta Irace
(C)
Serena Catalano
(S)
Davide Lauro
(D)
Davide Maggi
(D)
Eleonora Ambrosett
(E)
Marianna Maranghi
(M)
Daniela Pergolini
(D)
Maria Letizia Petroni
(M)
Francesca Marchignoli
(F)
Emanuela Orsi
(E)
Alessia Gaglio
(A)
Piermarco Piatti
(P)
Lucilla Monti
(L)
Paolo Pozzilli
(P)
Silvia Pieralice
(S)
Filippo Privitera
(F)
Roberto Trevisan
(R)
Mascia Albizzi
(M)
Raffaella Buzzetti
(R)
Angela Carlone
(A)
Dario Pitocco
(D)
Linda Tartaglione
(L)
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest DB has provided advisory board services for served as a consultant or speaker for Abbott, AstraZeneca, Sanofi and has received speaker fees for Abbott, Eli Lilly, Novo Nordisk, Roche Diagnostics and Sanofi. CI has provided advisory board services for Novo Nordisk, Lilly, Abbott, Menarini, Roche Diabetes Care, and Ascensia, and has received speaker fees for Novo Nordisk, Abbott, Senseonics, Lilly, and Boehringer Ingelheim Pharmaceuticals. GP has provided advisory board services for Dompè, speaker fees for Eli Lilly, Grant Recipient for Amgen Inc, Sanofi, Dompè, Abbott, Novo Nordisk, consulting fee from AstraZeneca, Sanofi, Eli Lilly, Enthera.